The U.S. Food and Drug Administration (FDA) has mandated that manufacturers of GLP-1 receptor agonists update product labels to include warnings about a potential link to non-arteritic anterior ischemic optic neuropathy (NAION).
The agency issued the announcement on Monday, citing the potential for the medications to cause serious vision issues, including sudden, painless, and potentially permanent loss of vision due to reduced blood flow to the optic nerve.
The regulatory action applies to widely used medications including Eli Lilly’s Mounjaro and Zepbound, as well as Novo Nordisk’s Ozempic and Wegovy. The same active ingredient, semaglutide, is also present in Novo Nordisk’s diabetes medication Rybelsus.
Research Findings on Vision Risks
The FDA identified a higher incidence of NAION among patients treated with GLP-1 medications compared to those receiving alternative glucose-lowering therapies. Investing.com reported that in clinical settings, the rate of NAION was 6.4 cases per 100,000 patient-years for GLP-1 users, compared to 3.8 cases per 100,000 patient-years in control groups.
Further analysis of the Sentinel network cohort revealed that GLP-1 treatments were associated with a 43% higher risk of NAION compared to DPP-4 inhibitors, though no statistically significant difference was observed when compared to SGLT-2 inhibitors.
A 2025 study cited by Haber Aktüel, which tracked approximately 175,000 diabetes patients, found that those treated with semaglutide faced a risk of NAION more than double that of patients using other medication classes after two years of use.
🚨BREAKING: FDA now requires a vision-loss warning on every GLP-1 label, from Ozempic and Wegovy to Mounjaro, Zepbound and Foundayo. The risk is NAION, a rare optic nerve event: 6.4 vs 3.8 cases per 100,000 patient-years across 126 trials.
EMA Classification and Patient Compensation in Denmark
The European Medicines Agency (EMA) previously concluded in 2025 that NAION should be classified as a very rare side effect for drugs containing semaglutide, potentially affecting one in 10,000 patients, according to Haber Aktüel. In Denmark, four patients have already received compensation after reporting vision loss linked to GLP-1 use.
Pharmaceutical companies maintain that the current data does not confirm a direct causal relationship. A Novo Nordisk spokesperson stated, “Novo believes the data does not establish a causal relationship and we have confidence in the benefit-risk profile of our GLP-1 medicines,” as reported by Haber Aktüel.
Eli Lilly stated that the FDA’s communication applies to the entire class of drugs and does not cite findings specific to Lilly’s products.
Risk Factors and Clinical Context
While the FDA has mandated these label updates, researchers emphasize that the patient population using these drugs often carries multiple pre-existing health conditions.
Symptoms That Require Immediate Medical Attention
What symptoms should prompt immediate medical attention?
Patients experiencing sudden, painless loss of vision or rapid changes in visual fields should seek emergency medical care immediately. Medical professionals advise that such symptoms should not be ignored or monitored for improvement, as they may indicate serious conditions including NAION or retinal vascular occlusions.
Are all patients at equal risk for this condition?
The risk is generally considered low, but Tıbbiye Bülteni reports that pre-existing conditions such as diabetes, hypertension, sleep apnea, smoking, and kidney disease are known risk factors for NAION. Because these conditions are common in patients prescribed GLP-1 drugs, researchers note that isolating the medication as the sole cause remains complex.
Should patients discontinue their medication?
Health authorities and manufacturers emphasize that patients should not alter or stop their prescribed treatment without first consulting their physician. The FDA’s decision is intended to inform healthcare providers and patients of the potential risk, rather than to suggest that the clinical benefits of these medications are outweighed by this specific side effect.
The FDA wants a new eye warning on every GLP 1 drug, Ozempic to Zepbound. Still rare: 6.4 optic nerve cases per 100,000 patient years vs 3.8 without them. Wall Street shrugged. $LLY up 4%, $NVO nearly 3%. Watch $LLY's $1,453 high; if it breaks, then the scare is priced in. pic.twitter.com/hTMtrkYBxA
Researchers are investigating whether GLP-1 medications directly trigger NAION, because the biological mechanism linking the drugs to optic nerve blood flow restriction is not yet fully understood.
More on Zepbound
Keep reading